Drug Profile
Research programme: monoclonal antibodies - GlycoForm/AstraZeneca
Alternative Names: GLYmAbLatest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator GlycoForm
- Developer GlycoForm (CEASED); MedImmune
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Dec 2011 Discontinued for Cancer in United Kingdom (Parenteral)
- 17 Jul 2006 Early research in Cancer in United Kingdom (Parenteral)